<DOC>
	<DOCNO>NCT03081598</DOCNO>
	<brief_summary>This Phase 2 , multi-center , double-blind , placebo-controlled study safety effect PBI-4050 dose range 400 mg 1200 mg relevant biomarkers subject inadequately-controlled T2DMS stable background antidiabetic therapy .</brief_summary>
	<brief_title>Study Evaluate Safety , Efficacy PBI-4050 &amp; Its Effect Relevant Biomarkers T2DM Patients With Metabolic Syndrome</brief_title>
	<detailed_description>This Phase 2 study perform 15 site Canada . The total duration study participation subject approximately 20 week comprise 6 study visit A total approximately 268 subject enrol study randomly assign one follow 4 treatment group : - PBI-4050 400 mg - PBI-4050 800 mg - PBI-4050 1200 mg - Placebo All subject receive assign study drug 12 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>1 . Subject 18 year age old . 2 . Subject sign write informed consent . 3 . Subject clinical diagnosis T2DM HbA1c level ≥ 7.5 % ≤ 10 % . 4 . Subject receive stable antidiabetic therapy ( without basal insulin ) minimum 3 month screen visit . 5 . Subject able willing selfmonitor blood glucose level home . 6 . Subject body mass index ( BMI ) ≥ 27 kg/m2 ≤ 45 kg/m2 . 7 . Subject metabolic syndrome , least 3 5 risk factor . 1 . Subject use prandial insulin premixed insulin addition oral hypoglycaemic agent blood glucose control . 2 . Subject take basal insulin dose &gt; 1.0 U/kg/day . 3 . Subject recent ongoing infection require systemic treatment antiinfective agent within 30 day screen . 4 . Subject history pancreatitis diabetic ketoacidosis . 5 . Subject least one episode severe hypoglycaemia past 12 month . 6 . Subject evidence significant cardiovascular disease within 3 month screen . 7 . Subject estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 . 8 . Subject uncontrolled hypertension . 9 . Subject diagnosis rheumatic inflammatory disease ; autoimmune inflammatory disease . 10 . Subject concurrently take plan routinely continue take antiinflammatory medication study . 11 . Subject currently use medication indication ( dos indicate ) weight loss . 12 . Subject significantly elevate liver enzyme level . 13 . History malignancy organ system , treat untreated , within past 5 year basal squamous cell skin cancer . 14 . Subject history chronic alcohol substance abuse . 15 . Subject history allergic reaction PBI4050 excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>